EP1267878A2 - Composes a activite agoniste sur le recepteur 5-ht utilises pour enrayer la perte du champ visuel - Google Patents

Composes a activite agoniste sur le recepteur 5-ht utilises pour enrayer la perte du champ visuel

Info

Publication number
EP1267878A2
EP1267878A2 EP01914447A EP01914447A EP1267878A2 EP 1267878 A2 EP1267878 A2 EP 1267878A2 EP 01914447 A EP01914447 A EP 01914447A EP 01914447 A EP01914447 A EP 01914447A EP 1267878 A2 EP1267878 A2 EP 1267878A2
Authority
EP
European Patent Office
Prior art keywords
compounds
glaucoma
compound
set forth
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01914447A
Other languages
German (de)
English (en)
Inventor
Robert J. Collier, Jr.
Mark R. Hellberg
Thomas R. Dean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of EP1267878A2 publication Critical patent/EP1267878A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention is directed to compounds with 5-HT] A agonist activity useful for controlling the visual field loss associated with glaucoma.
  • Glaucoma is a family of diseases, each of which is distinguished by a particular characteristic of that disease form.
  • Primary open angle glaucoma POAG
  • POAG Primary open angle glaucoma
  • IOP elevated intraocular pressure
  • NVG Normotension glaucoma
  • NVG low tension glaucoma
  • Other forms of glaucoma include closed angle glaucoma and pigmentary dispersion glaucoma. All these forms of glaucoma are similar in that patients suffer from the continued loss of nerve fiber layer and visual field.
  • MD mean deviation
  • CPSD corrected pattern standard deviation
  • the Eye Care Technology Forum has specifically recommended that for studies of glaucoma and ocular hypertension (OHT), analysis procedures be based on localized changes, such as are indicated by the CPSD. See, Johnson, Ophthalmology, Vol. 103, No. 1 (Jan., 1996).
  • Drug therapies that both lower IOP and provide additional protection to the retina and optic nerve head have been developed.
  • Compounds such as betaxolol and brimonidine have been shown to be neuroprotective in animal models. Both have been suggested to provide neuroprotection in glaucoma by direct penetration to the back of the eye after topical ocular administration.
  • Betaxolol's neuroprotection properties are believed to arise from its calcium channel blocking activities and its ability to stimulate the expression of key neuroprotective factors such as CNTF, bFGF, and BDNF.
  • Brimonidine is an 2 agonist and is believed to stimulate the production of bFGF.
  • Serotonergic 5-HT IA agonists have been reported as being neuroprotective in animal models and many of these agents have been evaluated for the treatment of acute stroke among other indications.
  • This class of compounds has been disclosed for the treatment of glaucoma (lowering and controlling IOP), see e.g., WO 98/18458 (DeSantis, et al) and EP 0771563 A2 (Mano, et al.).
  • Osbome, et al. (Ophthalmologica, Vol. 210:308-314, 1996) teach that 8-hydroxydipropylaminotetralin (8-OH-DPAT) (a 5-HT IA agonist) reduces IOP in rabbits. Wang, et al. (Current Eye Research, Vol.
  • 5-methylurapidil, .an ⁇ A antagonist and 5-HT iA agonist lowers IOP in the monkey, but due to its CC IA receptor activity.
  • 5-HTIA antagonists are disclosed as being useful for the treatment of glaucoma (elevated IOP) (e.g. WO 92/0338,
  • This invention is directed toward compounds that have potent agonist activity at 5-HT IA receptors.
  • the compounds are useful for controlling the visual field loss associated with glaucoma.
  • the Compounds can be delivered systemically or locally.
  • 5-HT agonists exhibit potent neuroprotective activity in the eye and as such have utility in controlling the visual field loss associated with glaucoma.
  • the invention contemplates the use of any pharmaceutically acceptable 5- HT IA agonist, including pharmaceutically acceptable salts, for controlling the visual field loss associated with glaucoma (Compounds).
  • Pharmaceutically acceptable means the Compounds can be safely used for the chronic treatment of glaucoma.
  • Compounds of the present invention have potent affinity for 5-HT ]A receptors with IC 5 o values that range up to about 500 nM (preferably less than 100 nM).
  • Compounds are also either full or partial agonists with IC 50 values ranging up to about
  • Representative 5-HTIA agonists useful according to the present invention include, but are not limited to: tandospirone, urapidil, ziprasidone, repinotan hydrochloride, xaliproden hydrochloride (SR-57746A), buspirone, flesinoxan, EMD-68843, DU-127090, gepirone, alnespirone, PNU-95666, AP-521, flibanserin, MKC-242, lesopitron, sarizotan hydrochloride, Org-13011, Org-12966, E-5842, SUN-N4057, and 8-OH-DPAT ⁇ .
  • Receptor binding and agonist activity according to this invention can be determined using the following methods.
  • 5-HT IA binding studies were performed with human cloned receptors expressed in Chinese hamster ovary (CHO) cells using ( 3 H)8-OH DP AT as the ligand.
  • Membranes from Chinese hamster ovary cells (CHO) expressing cloned 5-HT ⁇ A receptors were homogenized in approximately 40 volumes of 50 mM Tris pH 7.4 for 5 sec. Drug dilutions were made using a Beckman Biomek 2000 robot (Beckman Instruments, Fullerton, CA).
  • Ligand binding studies can also be run using membrane preparations from calf and rat brain (local source) and human cortex membranes. Specific brain regions were dissected out, homogenized in 10 volumes of 0.32 M sucrose and centrifuged for 10 min at 700 x g. The resulting supernatant was centrifuged at 43,500 x g for 10 min and the pellet re-suspended in 50 mM Tris-HCl (pH 7.7, 25°C) using a 10 sec polytron treatment. Aliquots were stored at -140° C. To remove endogenous serotonin, the preps were incubated at 37° C for 10 min prior to the experiment.
  • the function of Compounds of the present invention can be determined using a variety of methods to assess the functional activity of 5-HT ⁇ A agonists.
  • One such assay is performed using hippocampal slices from male Sprague-Dawley rats, measuring the inhibition of forskolin-stimated adenylate cyclase [J. Med. Chem. 42:36 (1999), J. Neurochem. 56: 1 1 14 (1991), J. Pharm. Exper. Ther. 284: 1082 (1998).
  • Rat hippocampal membranes were homogenized in 25 volumes of 0.3 M sucrose containing ImM EGTA, 5 mM EDTA, 5 mM dithiothreitol, and 20 mM Tris-HCl, pH
  • the homogenate was centrifuged for 10 m in at 1 ,000 x g. The supernatant subsequently was centrifuged at 39,000 x g for 10 min. The resulting pellet was re-suspended in homogenization buffer at a protein concentration of approximately 1 mg/ml and aliquots were stored at -140°C. Prior to use, the membranes were rehomogenized in a Potter-El vehj em homogenizer.
  • Xaliproden hydrochloride or vehicle was administered by intraperitonal (IP) injection at 48, 24, and 0 hours prior to light exposure.
  • Photo-oxidative injury to the retina was induced in dark-adapted rats (24 hours) by a 6-hour blue-light exposure (220 fc).
  • Control rats (N l l) were housed in their home cage under normal cyclic light exposure. Rats were single housed in clear polycarbonate cages during this light exposure.
  • ERG electroretinogram
  • Blue-light exposure for 6 hours resulted in a significant diminution of the ERG response amplitude (ANOVA, p ⁇ 0.001; Bonferroni t-test, p ⁇ 0.05) compared to normals when measured after a 5-day recovery period (Table 2).
  • Blue-light exposure resulted in a 50% reduction in the maximum a- and b-wave amplitudes in vehicle dosed rats compared to controls.
  • threshold responses were lower and evoked at brighter flash intensities.
  • New Zealand Albino or Dutch-belted rabbits (3 to 5 per arm) can be dosed topically with a solution formulation of Compound (1%) in the right eye and with vehicle in the left eye twice a day for a period of one week.
  • the ocular fluids and tissues are collected and analyzed for the presence of the drug via HPLC analysis.
  • the difference between the dosed eye and the contralateral vehicle dosed eye is a measure of the ability of the test item to penetrate directly to the retina/optic nerve head via topical ocular drug delivery.
  • the drug concentrations in the vehicle dosed eye represent delivery from systemic circulation.
  • the 5-HTIA agonists of this invention are administered orally with daily dosage of these compounds ranging between about 0.001 and about 500 milligrams.
  • the preferred total daily dose ranges between about 1 and about 100 milligrams.
  • Non-oral administration such as, intravitreal, topical ocular, transdermal patch, subdermal, parenteral, intraocular, subconjunctival, or retrobulbar or subtenon's injection, trans scleral (including iontophoresis), or slow release biodegradable polymers or liposomes may require an adjustment of the total daily dose necessary to provide a therapeutically effective amount of the Compound.
  • the 5-HT ⁇ A agonists can also be delivered in ocular irrigating solutions. Concentrations should range from about 0.001 ⁇ M to about 100 ⁇ M, preferably about 0.01 ⁇ M to about 5 ⁇ M.
  • the 5-HT 1A agonists can be incorporated into various types of ophthalmic formulations for delivery to the eye (e.g., topically, intracamerally, or via an implant). They may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, gelling agents, penetration enhancers, buffers, sodium chloride, and water to form aqueous, sterile ophthalmic suspensions or solutions or preformed gels or gels formed in situ.
  • Ophthalmic solution formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound.
  • the ophthalmic solutions may contain a viscosity enhancer, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl-pyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac.
  • a viscosity enhancer such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl-pyrrolidone, or the like.
  • the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum.
  • Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.
  • the 5-HT ⁇ A agonists are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 8.
  • the 5-HT )A agonists will normally be contained in these formulations in an amount .001% to 5% by weight, but preferably in an amount of .01% to 2% by weight.
  • 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the discretion of a skilled clinician.
  • the Compounds can also be used in combination with other agents for treating glaucoma, such as, but not limited to, ⁇ -blockers (e.g., timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol), carbonic anhydrase inhibitors (e.g., brinzolamide and dorzolamide), cti antagonists (e.g.
  • ⁇ -blockers e.g., timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol
  • carbonic anhydrase inhibitors e.g., brinzolamide and dorzolamide
  • cti antagonists e.g.
  • ⁇ 2 agonists e.g., iopidine and brimonidine
  • miotics e.g., pilocarpine and epinephrine
  • prostaglandin analogues e.g., latanoprost, travaprost, unoprostone, bimatoprost, and compounds set forth in U.S. Patent Nos. 5,889,052; 5,296,504; 5,422,368; 5,688,819; and 5,151,444, "hypotensive lipids” (e.g., compounds set forth in 5,352,708), and neuroprotectants (e.g., compounds from U.S. Patent No. 4,690,931, particularly eliprodil and R-eliprodil, as set forth in a pending application U.S.S.N. 06/203350, and appropriate compounds from WO94/13275, such as, memantine.
  • ⁇ 2 agonists e.g., i
  • topical ophthalmic formulations are useful according to the present invention administered 1-4 times per day according to the discretion of a skilled clinician.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés ayant une activité agoniste sur le récepteur 5-HT1A, lesquels composés sont utilisés pour enrayer la perte du champ visuel associée au glaucome.
EP01914447A 2000-03-17 2001-02-23 Composes a activite agoniste sur le recepteur 5-ht utilises pour enrayer la perte du champ visuel Withdrawn EP1267878A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
US190279P 2000-03-17
PCT/US2001/005740 WO2001070230A2 (fr) 2000-03-17 2001-02-23 Composes a activite agoniste sur le recepteur 5-ht utilises pour enrayer la perte du champ visuel

Publications (1)

Publication Number Publication Date
EP1267878A2 true EP1267878A2 (fr) 2003-01-02

Family

ID=22700682

Family Applications (3)

Application Number Title Priority Date Filing Date
EP01911005A Withdrawn EP1263434A1 (fr) 2000-03-17 2001-02-20 Composes a activite agoniste sur les recepteurs 5-ht 2? et 5-ht 1a? destines au traitement du glaucome
EP01914447A Withdrawn EP1267878A2 (fr) 2000-03-17 2001-02-23 Composes a activite agoniste sur le recepteur 5-ht utilises pour enrayer la perte du champ visuel
EP01918208A Expired - Lifetime EP1263504B1 (fr) 2000-03-17 2001-02-23 Utilisation de composes a activite agoniste sur le recepteur 5-ht1a destines au traitement des affections de la retine externe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01911005A Withdrawn EP1263434A1 (fr) 2000-03-17 2001-02-20 Composes a activite agoniste sur les recepteurs 5-ht 2? et 5-ht 1a? destines au traitement du glaucome

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01918208A Expired - Lifetime EP1263504B1 (fr) 2000-03-17 2001-02-23 Utilisation de composes a activite agoniste sur le recepteur 5-ht1a destines au traitement des affections de la retine externe

Country Status (19)

Country Link
EP (3) EP1263434A1 (fr)
JP (5) JP2003527423A (fr)
KR (3) KR20030016239A (fr)
CN (2) CN1198605C (fr)
AR (1) AR028258A1 (fr)
AT (1) ATE247507T1 (fr)
AU (5) AU2001238552A1 (fr)
BR (3) BR0109193A (fr)
CA (3) CA2400637A1 (fr)
DE (1) DE60100625T2 (fr)
DK (1) DK1263504T3 (fr)
ES (1) ES2204848T3 (fr)
HK (1) HK1051504A1 (fr)
MX (3) MXPA02009071A (fr)
PL (1) PL203709B1 (fr)
PT (1) PT1263504E (fr)
TW (1) TWI268777B (fr)
WO (3) WO2001070223A1 (fr)
ZA (1) ZA200206350B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
EP1263434A1 (fr) * 2000-03-17 2002-12-11 Alcon, Inc Composes a activite agoniste sur les recepteurs 5-ht 2? et 5-ht 1a? destines au traitement du glaucome
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
JP2006511556A (ja) 2002-12-13 2006-04-06 アルコン，インコーポレイテッド 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
WO2004096208A1 (fr) * 2003-04-25 2004-11-11 Mitsubishi Pharma Corporation Composition pour administration orale contenant un derive d'alkylene dioxybenzene
WO2005053688A1 (fr) 2003-11-26 2005-06-16 Alcon, Inc. Furo[2,3-g] indazoles substitues destines au traitement du glaucome
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (fr) 2003-12-15 2005-06-30 Alcon, Inc. [1,4]oxazino[2,3-g]indazoles substitues pour traiter le glaucome
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2400300A1 (fr) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Procédé de sélection d'agents préventifs/remèdes pour l'incontinence de stress
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
EP2018863B9 (fr) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné et utilisation
WO2008024846A2 (fr) * 2006-08-25 2008-02-28 Allergan, Inc. Compositions de brimonidine et de timolol
EP2896624B1 (fr) 2007-03-28 2016-07-13 Atir Holding S.A. Composés hétérocycliques comme agents sérotoninergiques et dopaminergiques et leurs utilisations
EP2216023A4 (fr) 2007-11-15 2013-03-13 Takeda Pharmaceutical Dérivé de pyridine condensé et son utilisation
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
WO2011071136A1 (fr) 2009-12-11 2011-06-16 アステラス製薬株式会社 Agent thérapeutique pour la fibromyalgie
EP2956096A1 (fr) 2013-02-15 2015-12-23 Allergan, Inc. Implant à administration de médicament prolongée
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
JP2022523774A (ja) 2019-02-27 2022-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
WO2023118544A1 (fr) * 2021-12-23 2023-06-29 Cilcare Dev Dérivés de 4-phényl-tétrahydropyridine pour le traitement de troubles auditifs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (fr) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
AU4249297A (en) * 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
EP1263434A1 (fr) * 2000-03-17 2002-12-11 Alcon, Inc Composes a activite agoniste sur les recepteurs 5-ht 2? et 5-ht 1a? destines au traitement du glaucome

Also Published As

Publication number Publication date
KR20030009390A (ko) 2003-01-29
WO2001070230A3 (fr) 2002-04-25
ES2204848T3 (es) 2004-05-01
CN1418121A (zh) 2003-05-14
EP1263504A2 (fr) 2002-12-11
CA2400637A1 (fr) 2001-09-27
DE60100625T2 (de) 2004-02-26
WO2001070222A2 (fr) 2001-09-27
DE60100625D1 (de) 2003-09-25
CN1198605C (zh) 2005-04-27
JP4789231B2 (ja) 2011-10-12
JP2003527427A (ja) 2003-09-16
JP2011037901A (ja) 2011-02-24
WO2001070230A2 (fr) 2001-09-27
ATE247507T1 (de) 2003-09-15
PL203709B1 (pl) 2009-11-30
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
CA2400639A1 (fr) 2001-09-27
CN1418100A (zh) 2003-05-14
AR028258A1 (es) 2003-04-30
KR20030016239A (ko) 2003-02-26
ZA200206350B (en) 2003-08-08
JP2011153158A (ja) 2011-08-11
AU2001239836A1 (en) 2001-10-03
CA2399985A1 (fr) 2001-09-27
WO2001070222A3 (fr) 2002-07-25
CA2400639C (fr) 2011-08-16
PL358306A1 (en) 2004-08-09
PT1263504E (pt) 2003-12-31
EP1263434A1 (fr) 2002-12-11
JP2003527423A (ja) 2003-09-16
HK1051504A1 (en) 2003-08-08
BR0109230A (pt) 2003-06-03
AU4531001A (en) 2001-10-03
WO2001070223A1 (fr) 2001-09-27
DK1263504T3 (da) 2003-12-08
BR0109193A (pt) 2003-05-27
AU2005202600B2 (en) 2008-07-31
MXPA02009071A (es) 2003-05-23
TWI268777B (en) 2006-12-21
KR20020082885A (ko) 2002-10-31
MXPA02009073A (es) 2003-03-12
KR100749191B1 (ko) 2007-08-13
JP2003527422A (ja) 2003-09-16
MXPA02009072A (es) 2003-03-12
EP1263504B1 (fr) 2003-08-20
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11

Similar Documents

Publication Publication Date Title
WO2001070230A2 (fr) Composes a activite agoniste sur le recepteur 5-ht utilises pour enrayer la perte du champ visuel
US7763619B2 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
US20060111388A1 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
AU2001245310A1 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
ZA200503230B (en) Histone deacetylase inhibitors for treating degenerative diseases of the eye.
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5965620A (en) Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US20030119846A1 (en) Compounds with 5-ht activity useful for controlling visual field loss
US20030114512A1 (en) Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17P Request for examination filed

Effective date: 20020830

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

18W Application withdrawn

Withdrawal date: 20021113